Toward the development of the true "off-the-shelf" synthetic T cell immunotherapy.

Recent outstanding clinical results demonstrated by engineered T cells, including chimeric antigen receptors, have already facilitated further researches that broaden their applicability. One such direction is to explore new T cell sources for allogeneic "off-the-shelf" adoptive immunotherapy. Human pluripotent stem cells may serve as an alternative cell source for this purpose due to its unique features of infinite propagation ability and pluripotency. Here, we describe the current state of engineered T cell transfer with the focus on cell manufacturing processes and the potentials and challenges of induced-pluripotent stem cell-derived T cells as a starting material to construct off-the-shelf T cell bank. This article is protected by copyright. All rights reserved.